Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01129765
Other study ID # AM-002
Secondary ID
Status Completed
Phase N/A
First received May 21, 2010
Last updated July 27, 2010
Start date July 2009
Est. completion date August 2009

Study information

Verified date July 2010
Source Aardvark Medical Company
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This study evaluates labeling comprehension, ease of use and effectiveness of a new device for nasal and sinus irrigation and/or aspiration. The device is currently cleared for professional use and home use with a prescription. This is a usability study to demonstrate that this device is appropriate for home use.


Description:

Nasal congestion is an important complication of viral upper respiratory infections in young children. It can lead to poor eating, sleeping and breathing. Recently, the FDA recommended against using over-the-counter cold remedies in young children because of inefficacy and occasional dangerous side effects. A commonly recommended non-drug solution for nasal congestion is nasal suctioning. This can be effective but currently available methods have been found to be awkward, uncomfortable and ineffective.

The studied device has potential for making nasal suctioning easy to perform in the home setting, especially in young children. It is already FDA cleared for professional use and this study was developed to demonstrate that it is appropriate for the home as well. This would be significant as it would allow parents a strategy of clearing their child's nose without drugs.

The device is automatic and handheld that can irrigate and/or aspirate the nasal cavity with hospital-grade suction. The handle houses a pump that can achieve air flows known to be effective for infant nasal suctioning in the hospital. A disposable wash-head is placed on top. It has an irrigation chamber with 0.9% saline and another chamber for collecting the aspirated nasal contents. The unit operates from a single bi-functional button.

Several key safety features have been built in such as: a tip that is shaped to maximize the seal but prevent intrusion into the nose; an irrigation function that delivers an optimal volume but prevents flooding the nasal cavity; and a pump that can deliver suction known to be effective in the hospital but whose safety valve does not allow it to rise above dangerous levels.

Participants were parents of children who have nasal congestion for whom nasal suctioning is traditionally recommended. They were asked to review the instruction manual of the device, and then use it on their children.

The primary outcome was proper use of device that was precisely defined. Additionally, subjective efficacy of mucus removal, evidence of adverse events and understanding of the device's user manual were also measured.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 2009
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group N/A to 5 Years
Eligibility Inclusion Criteria:

- Parents of children less than 6 years of age who were suffering from nasal congestion for which nasal suctioning and salt water irrigation/drops are prescribed.

Exclusion Criteria:

- Parents of children in marked respiratory distress or who maxillofacial malformations not conducive to nasal suctioning.

- Additionally, parents of children with recurrent nose bleeds, bleeding disorders or irritated peri-nasal skin were excluded.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Intervention

Device:
Use of an automatic nasal irrigator/aspirator
After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.

Locations

Country Name City State
United States Advanced Pediatrics Vienna Virginia

Sponsors (1)

Lead Sponsor Collaborator
Aardvark Medical Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Properly Used the Nasal Irrigator/Aspirator Device 'Proper use' is defined as successfully completing all of the following five steps:
Attaching wash-head to handle properly
Positioning child correctly for procedure as per the user manual's instructions
Using the device's control button correctly for both irrigation and aspiration
Placing the wash-head tip correctly at the nasal opening
Using the device for up to but not exceeding five seconds
Day one, immediately Yes
Secondary Number of Participants Who Experienced Ease of Use With the Device After using the device, the caregiver answered this question on a five point Likert-like scale with increasing favorability with increasing number. An answer of 3 or greater is considered an affirmative answer. Such responses reported along with the exact 95% confidence intervals.
The question and scale are as follows: How easy was the device to use?
1 difficult, 2 somewhat hard, 3 fairly easy, 4 easy, 5 very easy
Day one, immediately Yes
Secondary Number of Participants Who Found the Device to be Effective After using the device, the caregiver answered this question on a five point Likert-like scale with increasing favorability with increasing number. The proportion answering 3 or greater is reported along with the exact 95% confidence intervals.
The question and scale are as follows: How well did the device remove nasal secretions?
1 difficult, 2 somewhat hard, 3 fairly easy, 4 easy, 5 very easy
Day one, immediately No
Secondary Number of Participants Who Identified the Device's User Manual as Easy to Understand After using the device, the caregiver answered this question on a five point Likert-like scale with increasing favorability with increasing number. The proportion answering 3 or greater is reported along with the exact 95% confidence intervals.
The question and scale are as follows: How easy was the manual to understand?
1 difficult, 2 somewhat hard, 3 fairly easy, 4 easy, 5 very easy
Day one, immediately Yes
Secondary Number of Patients Who Were Observed to Have an Adverse Event While using the device, the patients were observed by the research coordinator for any of the following adverse events to occur:
bloody nose
being sprayed in the eye with the saline
vomiting after the procedure
choking during or after the procedure
other
Day one, immediately Yes
Secondary Number of Patients Experiencing a Physical Injury During Use After the procedure, the patient was directly examined for any of the following:
bleeding from the nostrils
disruption of the skin around the nose
increased work of breathing/respiratory distress (increased respiratory rate, increased respiratory accessory muscle use)
Day one, immediately Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05080322 - Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis Phase 4
Recruiting NCT06028490 - A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis. Phase 2
Completed NCT04388358 - Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation N/A
Recruiting NCT04202263 - Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline Phase 2
Completed NCT04078009 - Standardising Nasal Allergen Challenge in Adult With Hay Fever N/A
Completed NCT03644680 - Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study N/A
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Recruiting NCT05378594 - HDM and Silver Birch NAC Standardisation N/A
Not yet recruiting NCT05684380 - Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) Phase 3
Completed NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2
Completed NCT02910401 - Clinical Response to Rhinovirus Challenge Phase 2
Not yet recruiting NCT01014325 - Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy Phase 3
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Not yet recruiting NCT02233426 - Effect of Hypertonic Solutions on Allergic Rhinitis Patients N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT01946035 - Alpha-Blockers in Allergic Rhinitis (MAN 01) Phase 4
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Recruiting NCT01454492 - The Relationship Between Allergic Rhinitis and Geographic Tongue N/A
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2